Physician profile

Jonathan E Middlemiss

Physician Assistant · Salt Lake City, UT

NPI 1013317361

$4,486.52

in general payments reported to CMS, 2019-2025

7 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Consulting Fee$1,950.00
Travel and Lodging$577.10
Food and Beverage$205.92

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Si-Bone, INC. $4,288.79 2022-2024
Boston Scientific Corporation $67.99 2021-2022
Centinel Spine, LLC $35.17 2022
Globus Medical, INC. $34.61 2023 Creo 5.5
Depuy Synthes Sales INC. $22.69 2021
Nuvasive, INC. $20.75 2023 Modulus
Kci USA, INC. $16.52 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Jonathan E Middlemiss

$4,486.52

in general payments reported 2019-2025

Years
2021-2024
Top company
Si-Bone, INC.

https://glasscript.com/doctor/11135330/jonathan-e-middlemiss

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.